Category: Markets
Published: 2026-06-28T21:03:05.000Z
The FDA has approved Viridian Therapeutics' Lumvoa for treating both chronic and active phases of thyroid eye disease (TED), making it the second approved therapy after Amgen's Tepezza. Lumvoa offers competitive advantages, including a shorter dosing regimen, and Viridian plans to launch an autoinjectable version, elegrobart, in the future. Analysts expect Lumvoa to compete strongly in the multi-billion dollar TED market, with pricing likely similar to Tepezza.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.